Comorbid Diabetes Increases Risk for Lower Extremity Amputation With Kidney Disease
FRIDAY, Oct. 18, 2024 -- Patients with comorbid diabetes have an elevated risk for lower extremity amputation (LEA) at all stages of chronic kidney disease (CKD) compared with patients without diabetes, according to a study published online in the November issue of Journal of Diabetes and Its Complications.
Dhruv Nandakumar, from University of Texas Southwestern Medical School in Dallas, and colleagues evaluated the impact of diabetes on LEA rates in patients at various stages of CKD. The analysis included roughly 1.06 million patients with CKD and diabetes and 547,414 patients with CKD but no diabetes from 2010 to 2023.
The researchers found that rates of all LEA (overall, minor, and major LEA) were significantly higher at all CKD stages for patients with diabetes. For patients with diabetes and CKD stage 5, there was an increased likelihood of undergoing overall LEA (odds ratio [OR], 30.2), minor LEA (OR, 28.9), and major LEA (OR, 40.1) compared with patients without diabetes who had CKD stage 5. Independent of diabetes status, minor LEAs were performed with greater frequency than major LEAs across all stages of CKD. LEA rates significantly increased with CKD progression between stages 2 and 5 with comorbid diabetes, with a substantial jump between stages 4 and 5 (OR, 2.6). There were no significant increases in LEA rates with CKD progression between stages 1 and 2 in patients with diabetes.
“Foot and ankle surgeons who treat diabetes-related foot conditions should recognize the clinical consequences of worsening renal function,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
MONDAY, Sept. 8, 2025 -- The addition of baxdrostat, an aldosterone synthase inhibitor, to background therapy yields a significant reduction in seated systolic blood pressure...
Predialysis Nephrology Care Disparities Contribute to Vascular Access
FRIDAY, Sept. 5, 2025 -- System-based disparities in predialysis access to nephrology care contribute to disparities in the likelihood of having a mature, usable arteriovenous...
Mortality Rates From Hypertensive Renal Disease Increased From 1999 to 2023
FRIDAY, Sept. 5, 2025 -- From 1999 to 2023, there was an increase in age-adjusted mortality rates (AAMRs) for hypertensive renal disease, according to a study presented at the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.